Skip to main content
. Author manuscript; available in PMC: 2018 Dec 14.
Published in final edited form as: Oncogene. 2014 Aug 11;34(22):2823–2835. doi: 10.1038/onc.2014.228

Figure 4.

Figure 4.

Effects of Myc activity on Tsp-1 expression. (a) Immunoblot analysis of Tsp-1, β-Actin and Ras proteins expressed by kidney- derived cells expressing high levels of oncogenic Ras plus dominant-negative MycER after various treatment times with 4-HT. (b) Immunoblot analysis of Tsp-1, β-Actin and Ras proteins expressed by kidney-derived cells expressing low levels of oncogenic Ras plus MycER after various treatment times with 4-HT. (c) Immunoblot analysis of Myc, β-Actin and Ras proteins in low Ras cells expressing MycER (wt) and high Ras cells expressing DNMycER (DN). (d) Immunoblot analysis of Tsp-1, phospho Myc, β-Actin and Ras proteins expressed by kidney-derived cells expressing high levels of oncogenic Ras transfected with S62AMyc (62) or S71AMyc (71) genes. (e) Immunoblot analysis of Tsp-1, β-Actin and Ras proteins expressed by kidney-derived cells expressing low levels of oncogenic Ras, or high levels of oncogenic Ras that were mock transfected or transfected with S62AMyc (62) and S71AMyc (71) genes. (f) Ribonuclease protection assay of ODC and cyclophilin expressed in kidney-derived cells expressing no oncogenic Ras (−), low levels of oncogenic Ras, or high levels of oncogenic Ras that were mock transfected or transfected with wtMyc (58), S62AMyc (62) or S71AMyc (71) genes. Black lines represent cases where lanes were digitally removed from the scanned image.